RSPH6A

Across TCGA pan-cancer cohorts, RSPH6A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RSPH6A data layer compared with 19 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RSPH6A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RSPH6A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, PRAD, and LUSC are the cancer types where RSPH6A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.015	6	view →
LUSC	DFS	Median	All	0.326	0.719	.012	4	view →
COAD	DFS	Median	All	0.133	0.567	.011	4	view →
UCEC	OS	Median	All	1.000	0.654	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RSPH6A–LIHC (DFS)

Open the LIHC breakdown →